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Background:  There is limited information on anticoagulation control among atrial fibrillation/flutter (AF/AFL) patients (pts) receiving combined 
warfarin (W) and antiarrhythmic drug (AAD) therapy in the real-world setting.
Methods:  This retrospective cohort study identified AF/AFL pts ≥18 yrs with concurrent pharmacy claims (≥ 60 days’ supply within first 90 days of 
initiating treatment) for W and a Class I/III AAD from the Ingenix IMPACT database (1997-2009). Eligible pts had to have ≥1 claims with an AF/AFL 
diagnosis ≤6 months before the first date of concomitant W + AAD use (‘index date’) and continuous pre- (≥6 months) and post-index (≥12 months) 
enrollment. Study cohorts comprised pts receiving exclusively either (i) W + amiodarone (A) or (ii) W + another antiarrhythmic (OAAD). International 
normalized ratio (INR) monitoring frequency and time with INR below/within/above the therapeutic range (2 ≤ INR ≤ 3) were determined over 12 
months post-index.
Results:  4,238 pts (mean age 66.5 yrs; 70% male; Charlson Comorbidity Index [CCI] score 1.76) received W + A and 6,332 pts (mean age 61.9 
yrs; 65% male; CCI score 0.89) received W + OAAD. Laboratory data were available for 1,471 pts on W + A and 2,250 pts on W + OAAD; among this 
subset, 714 (48.5%) W + A pts and 952 (42.3%) W + OAAD pts had ≥1 post-index INR test. The mean (±SD) number of INR tests/week was similar 
in W + A pts and W + OAAD pts with lab data (0.08 ± 0.15 vs 0.07 ± 0.12). Among pts with INR data over 12 months post-index, the mean (±SD) 
percent of time below the therapeutic range was similar for W + A pts and W + OAAD pts (39.1 ± 35.0% vs 38.7 ± 35.4%; P=0.489). However, W + 
A pts experienced a lower mean percent of time within the therapeutic range than W + OAAD pts (40.9 ± 33.5% vs 47.0 ± 34.1%; P=0.0011) and a 
higher mean percent of time above the therapeutic range than W + OAAD pts (19.9 ± 27.4% vs 14.3 ± 22.7%; P<0.0001)
Conclusions:  In real-world practice, AF/AFL pts treated with W + A tend to be older and have more severe comorbidity than pts on W + OAAD. Pts 
experience more fluctuation in INR outside the therapeutic range during combination W + A than W + OAAD therapy. Additional study is required to 
investigate these findings further.
